Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma.

BMC Cancer · 2016 · PMC4845347 · PMID 27114074

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Two pivotal phase III trials (MM-009 and MM-010) have demonstrated highly significant improvement of response rates with lenalidomide/dexamethasone compared with placebo/dexamethasone in a total of 704 RMM patients and subsequently led to regulatory approval of lenalidomide in the USA and the EU.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.